Modality
ASO
MOA
CAR-T BCMA
Target
BCL-2
Pathway
Lipid Met
CholangiocarcinomaRCC
Development Pipeline
Preclinical
~Aug 2023
→ ~Nov 2024
Phase 1
Feb 2025
→ Nov 2027
Phase 1Current
NCT05973124
2,104 pts·Cholangiocarcinoma
2025-02→2027-11·Active
2,104 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-11-161.6y awayInterim· Cholangiocarcinoma
Trial Timeline
Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1
Active
Catalysts
Interim
2027-11-16 · 1.6y away
Cholangiocarcinoma
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05973124 | Phase 1 | Cholangiocarcinoma | Active | 2104 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-4339 | Argenx | Phase 2 | BCL-2 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn |